281

178. Martínez Roig A, Camí J, LLorens Terol J, de la

Torre R, Perich F. Acetylation phenotype and

hepatotoxicity in the treatment of tuberculosis

in children. Pediatrics. 77. 912-915, 1986.

179. Martínez Jordà R. Estudio del fenotipo acetilador en

el País Vasco. Actas 5a. Reunión de la Asociación

Española de Farmacología. Tenerife, 1980.

180. Mazze RI, Woodruff RE, Heerdt E. Isoniaz id-induced

enflurane defluorination in humans.

Anesthesiology , 57 , 528, 1982.

181. McGeer PL, McGeer EG, Suzuki JS. Aging and

extrapyramidal function. Arch Neurol, 34, 33-35,

1977.

:E

182. McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward

JW. Pharmacokinetics and beta-blocking effects of

timolol in poor and extensive metabolizers of

debrisoquin. Clin Pharmacol Therf 3_8, 409-413,

1985.

282

183. McLaren EH, Burden AC, Moorhead PJ. Acetylator

phenotype in diabetic neuropathy. Br Med J. 2.,

291-293, 1977.

184. McQueen EG. Pharmacological basis of adverse drug

reactions. A Avery (dir) Drug Treatment, 2a ed,

pp 202-235. Adis Press, Sydney.

185. Mellstròm B, Swe J, Bertilsson L, Sjòqvist F.

Amitriptyline metabolism: associaton with debrisoquin

hydroxylation in nonsmokers. Clin Pharmacol Therf

39. 369-371, 1986.

186. Mellstròm B, Bertilsson L, Swe J, Schulz HV,

Sjòqvist F. E-and Z-10-hydroxylation of

nortriptyline: relationship to polymorphic

debrisoquine hydroxylation. Clin Pharmacol Ther.

3_0, 189-193, 1981.

187. Miller ME, Garland WA, Min BH, Ludwick BT, Ballard

RH, Levy RH. Clonazepam acetylation in fast and slow

283

acetylators. Clin Pharmacol Ther. 30f 343-347,

1981.

188. Miller ME. Acetylator phenotype in bladder cancer.

Lancet. 2., 1348, 1982.

189. Miller ME, Cosgriff JM. Acetylator phenotype in human

bladder cancer. J Urolf I30f 65-66, 1983.

190. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA,

Snodgrass WR, Potter WZ, Jollow DJ, Reiser HR.

Increased incidence of isoniazid hepatitis in rapid

acetylators: possible relation to hydrazine metabolites

Clin Pharmacol Ther. 18, 70-79, 1975.

191. Mitchell SC, Waring RH, Haley CS, Idle JR, Smith RI.

Genetic aspects of the polymodally distributed

sulphoxidation of S-carboxymethyl-L-cysteine in man.

Br J Clin Pharmacol. 18. 507-521, 1984.

192. Molin L, Larsson R, Karlsson E. Evaluation of the

284

sulphapyridine acetylator phenotyping test in healthy

subjects and in patients with cardiac and renal

diseases. Acta Med Scandf 201, 217-222, 1977.

193. Moore MR. International review of drugs in acute

porphyria - 1980. Int J Biochem. 12, 1089-1097, 1980.

194. Moore MR. McColl KEL, Goldberg A. Drugs and the acute

porphyrias. Trends Pharmacol Sci. 2., 330-334, 1981.

195. Morris RJ, Freed CR, Kohler PF. Drug acetylation

phenotype unrelated to development of spontaneous

systemic lupus erythematosus. Arthr Rheum. 22,

777-780, 1979.

196. Motulski AG, Yoshida A, Stamatoyannopoulos G.

Glucose-6-phosphate dehydrogenase variants. Ann NY

Acad Sci. 179r 636, 1971.

197. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E,

Wilkinson GR, Branch RA. Interethnic differences in

genetic polymorphism of debrisoquin and mephenytoin

285

between Japanese and Caucasian populations. Clin

Pharmacol Ther. 38. 402-408, 1985.

198. O'Reilly RA, Aggeler PM, Hoag MS, Leong LS, Kropatkin

ML. Hereditary transmission of exceptional resistance

to coumarin anticoagulant drugs. The first reported

kindred. N Encfl J Med. 721. 809, 1964.

199. Gates NS, Shah RR, Idle JR, Smith RL. Genetic

polymorphism of phenformin 4-hydroxylation. Clin

Pharmacol Ther. 32, 81-89, 1982.

200. Dates NS, Shah RR, Idle JR, Smith RL. Influence of

oxidation polymorphism on phenformin kinetics and

dynamics. Clin Pharmacol Ther. 34, 827-834, 1983.

201. Oka M, Seppala O. Acetylation phenotype in rheumatoid

arthritis. Scand J Rheumatol. 7., 29-30, 1978.

202. Olsen H, Morland J. Ethanol-induced increase in drug

acetylation in man isolated rat liver cells. Br Med Jf

2, 1260-1262, 1978.

286

203. Otton SV, Inaba T, Kalow W. Inhibition of sparteine

oxidation in human liver by tricyclic antidepressants

and other drugs. Life SciF 32. 795-800, 1983.

204. Otton SV, Inaba T, Kalow W. Competitive inhibition of

sparteine oxidation in human liver by

beta-adrenoceptor antagonists and other

cardiovascular drugs. Life Sci. 34, 73-80, 1984.

205. Osborne KH, De George FV. Genetic basis of

morphological variation, an evaluation and aplication

of the twin study method. Harvard University Press.

Cambridge Mass, 1959.

206. Panayi GS, Huston G, Shah RR, Mitchell SC, Idle JR,

Smith , Waring RH. Deficient sulphoxidation status

and D-penicillamine toxicity. Lancet. JL, 414,

1983.

207. Paulsen O, Nilsson LG. Distribution of acetylator

phenotype in relation to age and sex in Swedish

patients. Eur J Clin Pharmacolf 28, 311-315, 1985.

287

208. Paykel ES, West PS, Rowan PR, Parker RR. Influence of

acetylator phenotype on antidepressant effects of

phenelzine. Br J Psychiatry, 141, 243-248, 1982.

209. Peart GF, Boutagy J, Shenfield GN. Debrisoquin

oxydation in an Australian population. Br J Clin

Pharmac. 21, 465-471, 1986.

210. Penno MB, Vesell ES. Monogenic control of variations

in antipyrine metabolite formation: new polymorphism

of hepatic drug oxidation. J Clin Invest. 71.

1698-1709, 1983.

211. Perry Jr HM. Late toxicity to hydralazine resembling

systemic lupus erythematosus or rheumatoid arthritis.

Am J Med. 54, 58-71, 1973.

212. Perry Jr HM, Tan EM, Cordoby S, Sahamato A.

Relationship of acetyltransferase activity to

antinuclear antibodies and toxic symptoms on

hypertensive patients treated with hydralazine.

J Laborat Clin Med. 76. 114-125, 1970.

288

213. Peters JH, Gordon GR, Murray JF. Metabolic

disposition of dapsone in African leprosy patients.

Leprosy Rev, 50. 7-19, 1979.

214. Peters JH, Murray JF, Gordon GR, Gelber RH. Dapsone

in saliva and plasma of man. Pharmacology. 22f

162-171, 1981.

215. Petrakis NL, Wiesenfeld SL, Sams RJ, Collen MF,

Cutler JL, Siegelaub AB. Prevalence of sickle-cell

trait and glucose-6-phosphate dehydrogenase

deficiency. N Enql J Med. 282. 767, 1970.

216. Philips PA, Rogers HJ, Millis RR, Rubens RD, Cartwight

RA. Acetylator status and its relationship to breast

cancer and other diseases of the breast. Eur J Cancer

Clin Oncol. 21, 1701-1706, 1987.

217. Poirier J, Roy M, Campanella G, Cloutier T, Paris S.

Debrisoquine metabolism in parkinsonism patients

treated with antihistamine drugs. Lancet. 2.,

386, 1987.

289

218. Poland A, Glover E. 2,3,7,8,-Tetrachlorodibenzo-p-dioxin:

a potent inducer of delta-aminolevulinic acid synthetase,

Science. 179f 476, 1973.

219. Pontiroli AE, De Pascua A, Bonisoli L, Pozza G.

Ageing and acetylator phenotype as determined by

administration of sulphadimidine. Eur J Clin

Pharmacol. 28f 485-486, 1985.

220. Prankerd TAJ. The Red Cell. Thomas. Springfield, 1961.

221. Prankerd TAJ. Glucose-6-phosphate dehydrogenase

deficiency. Proc R Soc Med. 57, 506-508, 1964.

222. Price Evans DA, Eze LC, Whibley EJ. The association

of the slow acetylator phenotype with bladder

cancer. J Med Genetics. 20, 330-333, 1983.

223. Price Evans DA, Harmer D, Downham DY, Whibley EJ,

Idle JR, Ritchie J, Smith RL. The genetic control of

sparteine and debrisoquine metabolism in man with new

290

methods of analysing bimodal distributions. J Med

Genetics. 20f 321-329, 1983.

224. Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith

RL. A family and population study of the genetic

polymorphism of debrisoquine oxidation in a white

British population. J Med Genetics. 17, 102-105,

1980.

225. Price Evans DA, Manley KA, McKussick VÀ. Genetic

control of isoniazid metabolism in man. Br Med Jf

2., 485-491, 1960.

226. Price Evans DA, White TA. Human acetylation

polymorphism. J Laborat Clin Medf 63, 394-403,

1964.

227. Raghupati Sarma G, Kailasam S, Nair NGK, Narayana

ASL, Tripathy SP. Effect of prednisolone and

rifampicin on isoniazid metabolism in slow and rapid

inactivators of isoniazid. Antimicr Ag Chemother, 18,

661-666, 1980.

291

228. Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJJ.

Polymorphic ability to metabolize propranolol alter

4-hydroxypropranolol levels but not beta blockade.

Clin Pharmacol Ther. 36, 51-56, 1984.

229. Ramsay LE, Silas JH, Ollerenshaw JD, Tucker GT,

Phillips FC, Freestone S. Should the acetylator

phenotype be determined when prescribing hydralazine

for hypertension. Eur J Clin Pharmacol. 26P

39-42, 1984.

230. Rao KVN, Mitchison DA, Nair NGK, Prema K, Tripathy

SP. Sulphadimidine acetylation test for

classificaction of patients as slow or rapid

inactivators of isoniazid. Br Med J. 3., 495-497,

1970.

231. Redondo FL, Miralles E, Bergón E, Ramos V.

Acetilación hepática en la población española

(carta). Gastroenterol Hepatol. 1, 107, 1980.

292

232. Reece PA, Cozamanis I, Zacest R. Kinetics of

hydralazine and its main metabolites in slow and fast

acetylators. Clin Pharmacol Ther. 28, 769-778,

1980.

233. Reidenberg MM. The clinical induction of systemic

lupus erythematosus and lupus-like illnesses. Arthr

Rheumat. 24. 1005-1009, 1981.

234. Reidenberg MM, Drayer DE, Levy M, Warner H.

Polymorphic acetylation of procainamide in man. Clin

Pharmacol Ther. 17. 722-730, 1975.

235. Reidenberg MM, Levy M, Drayer DE, Zylber-Katz E,

Robbins WC. Acetylator phenotype in idiophatic

systemic lupus erythematosus. Arthr Rheumat. 23,

569-573, 1980.

236. Reidenberg MM, Martin JH. The acetylator phenotype of

patients with systemic lupus erythematosus. Drug

Metab Disp. 2, 71-73, 1974.

293

237. Ritchie JC, Sloan TP, Idle JR, Smith RL.

Toxicological implications of polymorphic drug

metabolism. In Environmental chemicals, enzyme

function and human disease. CIBA Foundation

Symposium, 76, 219-224, 1980.

238. Robson JM, Sullivan FM. Antituberculosis drugs.

Pharmacol Rev, 15, 169-223, 1963.

239. Roden DN, Reele SB, Higgins SB, Mayol RF, Gammans RE,

Dates JA, Woosley RL. Total suppression of ventricular

arrhythmias by encainide. N Engl J Med. 302.

878-882, 1980.

240. Roden DN, Reele SB, Higgins SB, Smith R, Gates JA,

Woosley RL. Antiarrhythmic efficacy, pharmacokinetics

and safety of N-acetylprocainamide in man. Am J

Cardiol. 46. 463-468, 1980.

241. Rose S. The relationship of acetylation phenotype to

treatment with MAOIs: A review. J Clin

Psychopharmacol, 2., 161-164, 1982.

294

242. Rothfield NF, Bierer WF, Garfield JW. Isoniazid

induction of antinuclear antibodies, a prospective

study. Ann Intern Med. 88. 650-652, 1978.

243. Sanders GL, Rawlins MD. Phenelzine: acetylator status

and clinical response. Br J Clin Pharmacol. 7_,

451-452, 1979.

244. Saucedo R, Mayor B, Puche E. Estudio del fenotipo

acetilador en Andalucía. Rev Clin Esp. 177,

75-77, 1985.

245. Schmid B, Bircher J, Preising R, Kupfe A. Polymorphic

dextrometorfan metabolism: cosegregation of oxydative

O-demethylation with debrisoquin hydroxylation. Clin

Pharmacol Ther. 38. 618-624, 1985.

246. Schroeder P, Kligaard NA, Simonsen E. significance of

the acetylation phenotype and the therapeutic effect

of procainamide. Eur J Clin Pharmacol. 15, 63-68,

1979.

V.--

295

247. Scott EM. The relation of diaphorase of human

erythrocytes to inheritance of methemoglobinemia.

J Clin Invest. 39. 1176, 1960.

248. Scott J, Poffenbarger PL. Pharmacogenetics of

tolbutamide metabolism in humans. Diabetes, 28,

41-51, 1979.

249. Shah RR, Gates NS, Idle JR, Smith RL. Beta-blockers

and drug oxidation status. Lancet, I, 508-509,

1982.

250. Shah RR, Gates NS, Idle JR, Smith RL, Lockhart JDF.

Impaired oxidation of debrisoquine in patients with

perhexiline neuropathy. Br Med J. 284f 295-299,

1982.

251. Sharp ME, Wallace S, Hindmarsh KW, Brown MA.

Acetylator phenotype and serum levels of

sulphapyridine in patients with inflammatory bowel

disease. Eur J Clin Pharmacolf 21. 243-250, 1981.

296

252. Shepherd AMM, Lin M-S, McNay J, Ludden T, Musgrave G.

Determinants of response to intravenous hydralazine

in hypertension. Clin Pharmacol Therf 30.

773-781, 1981.

253. Shepherd AMM, McNay JL, Ludden TM, Lin M-S, Musgrave

GE. Plasma concentration and acetylator phenotype

determine response total hydralazine. Hypertension. 3.,

580-585, 1981.

254. Silas JH, Lennard MS, Tucker GT, Smith AJ, Malcolm SL,

Marten TR The disposition of debrisoquine in hypertensive

patients. Br J Clin Pharmacol. 5_, 27-34, 1978.

255. Singlas E, Goujet MA, Simon P. Pharmacokinetics of

perhexiline maléate in anginal patients with and

without peripheral neuropathy. Eur J Clin

Pharmacol. 14. 195-201, 1978.

256. Sjòqvist F, Borga O, Orme MLE. Fundamentals of

clinical pharmacology. A Avery (dir), Drug

297

Treatmentf 2» ed, 32-33. ADIS Press, Sydney, 1980.

257. Sloan TP, Idle JR, Smith RL. Influence of D"/D'

alíeles regulating debrisoquine oxidation of

phenytoin hydroxylation. Clin Pharmacol Ther. 29f

493-497, 1981.

258. Sloan TP, Lancaster R, Shah R, Idle JR, Smith RL.

Genetically determined oxidation capacity and the

disposition of debrisoquine. Br J Clin Pharmacol.

15, 443-450, 1983.

259. Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL.

Polymorphism of carbon oxidation of drugs and

clinical implications. Br Med J, 2f 655-657,

1978.

260. Smith RL, Idle JR, Mahgoub AA, Sloan TP, Lancaster R.

Genetically determined defects of oxidations at

carbon centres of drugs. Lancet. 1, 943-944, 1978.

298

261. Sonnhag C, Karlsson E, Hed J. Procainamide-induced

erythematosus-like syndrome in relation to acetylator

phenotype and plasma levels of procainamide. Acta

Med Scand. 206. 245-251, 1979.

262. Spina E, Steiner E, Ericsson, Sjòqvist F.

Hydroxylation of demethylimipramine: dependence on

the debrisoquin hydroxylation phenotype. Clin

Pharmacol Ther. 41. 314-319, 1987.

263. Spina E, Bigersson C, von Bahr Ch, Ericsson,

Steiner E, Sjòqvist F. Phenotyping consistency in

hydroxylation of demethylimipramine and debrisoquine

in healthy subjects in human liver microsomes. Clin

Pharmacol Ther. 36. 677-682, 1984.

264. Steiner E, Iselius L, Alvan G, Lindsten J, Sjòqvist

F. A family study of genetic and environmental factors

determining polymorphic hydroxylation of debrisoquin.

Clin Pharmacol Ther. 3_8, 394-401, 1985.

299

265. Steiner E, Alván G, Garle M, Maguire JH, Lind M,

Nilsson S-O, Tomson T, McClanahan JS, Sjòqvist F. The

debrisoquin hydroxylation phenotype does not predict

the metabolism of phenytoin. Clin Pharmacol Therf

42., 326-333, 1987.

266. Steiner E, Bertilsson L, Swe J, Berthing I, Sjòqvist

F. Polymorphic debrisoquine hydroxylation in 757

Swedish subjects. Clin Pharmacol Ther, 44, 431-435,

1988.

267. Stephen PJ, Williamson J. Drug-induced parkinsonism

in the elderly. Lancet. 2., 1082-1083, 1984.

268. Steventon G, Williams AC, Waring RH, Pall HS, Adams

D. Xenobiotic metabolism in motoneuron disease.

Lancet. 2_, 644-647, 1988.

269. Strandberg I, Boman G, Hasster L, Sjòqvist F.

Acetylator phenotype in patients with

hydralazine-induced lupoid syndrome. Acta Med

300

Scand. 200. 362-371, 1976.

270. Suhardjono D, Boutagy JS, Shenfield GM. Influence of

blood glucose on acetylation status (Abstract). Clin

Exp Pharmacol Phvsiol. Suppl 8, 64, 1984.

271. Surana MK, Mathur AK, Banerjee K, Agarwal TD.

Correlation between acetylator phenotype and

neuropathy in diabetes mellitus patients. J

Ass Physicians India, 30, 437-439, 1982.

272. Syvlahti EKG, Lindberg R, Kallio J, de Vocht M.

Inhibitory effects of neuroleptics on debrisoquine

oxidation in man. Br J Clin Pharmacol, 22, 89-92,

1986.

273. Szórády I, Santa A. Drug hydroxylator phenotype in

Hungary. Eur J Clin Pharmacol. 32f 325, 1987.

274. Talseth T, Landmark KH. Polymorphic acetylation of

sulphadimidine in normal and uraemic man. Eur J Clin

301

Pharmacol , 11, 33-36, 1977

275. Tang BK, Kadar D, Kalow W. An alternative test for

acetylator phenotyping with caffeine. Clin Pharmacol

Ther. 42., 509-513, 1987.

276. Thorn S, Farrow PR, Santoso B, Alberti KGMM, Rawlins

MD. Effects of oral glucose in lime juice on isoniazid

kinetics. Br J Clin Pharmacol. 11, 423P, 1981.

277. Timbrell JA, Harland SJ, Facchini V. Polymorphic

acetylation of hydralazine. Clin Pharmacol Ther.

28. 350-355, 1980.

278. Timbrell JA, Wright JM, Baillie TA. Monoacetyl-

hydrazine as a metabolite of isoniazid in

man. Clin Pharmacol Ther. 22, 602-608, 1977.

279. Valsalan VC, Cooper GL. Carbamazepine intoxication

caused by interaction with isoniazid. Br Med J.

285. 261-262, 1982.

302

280. Vandenburg MJ, Wright P, Holmes J, Rogers HJ, Ahmad

RA. The hypotensive response to hydralazine, in

triple therapy, is not related to acetylator

phenotype. Br J Clin Pharmacol. 13. 747-750,

1982.

281. Vansant J, Woosley RL, John JT, Sergent JS. Normal

distribution of acetylation phenotypes in systemic

lupus erythematosus. Arthr Rheumat. 21. 192-195,

1978.

282. Vasko MR, Bell RD, Daly DD, Pippenger CE. Inheritance

of phenytoin hypometabolism: a kinetic study of one

family. Clin Pharmacol Therf 27, 96-103, 1980.

283. Vesell ES, Ng L, Passanant! GT, Chase TN. Inhibition

of drug metabolism by levodopa in combination with a

dopa-decarboxylase inhibitor. Lancet, 2., 370, 1971.

284. Vesell ES. Why individuals vary in their response to

drugs, 1980. Trends Pharmacol Sci. JL, 349-351,

1980.

303

285. Vesell ES, Penno MB. Assessment of methods to

identify sources of interindividual pharmacokinetic

variations. Clin Pharmacokin. jJ, 378-409, 1983.

286. Voguel F, Motulski AG. Human genetics. Problems and

approaches. Springer Verlag, Berlin, Heid NY, 1979.

287. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R,

Calne DR. Parkinson's disease in 65 pairs of twins

and in a set of quadruplets. Neurology, 33.

815-824, 1983.

288. Waring RH, Mitchell SC, Shah RR, Idle JR, Smith RL.

Polymorphic sulphoxidation of S-carboxymethyl-L-

-cysteine in man. Biochem Pharmacolf 31, 3151-3154,

1982.

289. Wasserman RH, Taylor AN. Vitamin 03-induced

calcium-binding protein in chick intestinal mucose.

Science, 152, 791, 1966.

•EJft> >; '. >,.

304

290. Weber WW, Hein DW. Clinical pharmacokinetics of

isoniazid. Clin Pharmacokin. 94, 401-422, 1979.

291. Weber WW, Glowinski IB. Acetylation. A Jakoby

(dir), Enzymatic basis for detoxication. 169-186.

Academic Press, Nova York, 1980.

292. Weinshilboum RM. Biochemical genetics of

catecholamines in humans. Mayo Clin Proc.

58. 319-330, 1983.

293. White TA, Price Evans DA. The acetylation of

suphamethazine and sulphamethoxypyridazine by human

subjects. Clin Pharmacol Ther. 9_, 80-88, 1968.

294. Winters RW, Graham JB, Williams TF, McFalls VW,

Burnett CH. A genetic study of familial

hypophosphatemia and vitmamin D resistant rickets.

Transact Ass Amer Physicians. 70. 234, 1957.

295. Wiholm BE. El sistema sueco de detección y

305

cuantificación de reacciones adversas a medicamentos.

A Laporte J i Laporte JR (dirs), Avances en

terapéutica, vol 15. 44-63. Salvat. Barcelona,

1988.

296. Wolf H, Lower Jr GM, Bryan GT. Role of

N-acetyltransferase phenotype in human susceptibility

to bladder carcinogenic arylamines. Scand J Urol

Nephrol. 14. 161-165, 1980.

297. Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR,

Smith RL. Debrisoquine hydroxylation polymorphism

among Ghanaians and Caucasians. Clin Pharmacol

Ther. 26. 584-591, 1979.

298. Woolhouse NM, Atu-Taylor LC. Influence of double

genetic polymorphism on response to sulfamethazine.

Clin Pharmacol Ther. 31. 377-383, 1982.

299. Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr

K, Gates JA. Effect of acetylator phenotype on the

-', Yv*.-:-

306

rate at which procainamide induces antinuclear

antibodies and the lupus syndrome. N Encfl J Med,

!, 1157-1159, 1978.

300. Woosley R, Roden DM, Dai G, Wang T, Altenberg D, Gates J,

Wilkinson G. Co-inheritance of the polymorphic metabolism

of encainide and debrisoquine. Clin Pharmacol Ther. 39 ,

282-287, 1986.

301. Woosley RL, Roden DM, Duff HG, Carey BL, Wood AJJ,

Wilkinson GR. Coinheritance of deficient oxidative

metabolism of encainide and debrisoquine. Clin Res,

29. 501A, 1981.

302. Ylitalo P, Ruosteenoja R, Leskinen O, Mets-Ketel T.

Significance of acetylator phenotype in

pharmacokinetics and adverse effects of procainamide.

Eur J Clin Pharmacol. 25. 791-795, 1983.

303. Yoshida A. Hemolytic anemia and G6PD deficiency.

Science. 179. 532, 1973.

307

304. Young JR. Acetylator status and liver function

profile changes in labyrinthine ischaemia patients

with thymoxamine. Int J Med Res, 8., 356-357,

1980.

305. Zacest R, Koch-Weser J. Relation of hydralazine

plasma concentration to dosage and hypotensive

action. Clin Pharmacol Therf 13, 420-425, 1972.

306. Zidek Z, Janku I. Estrogen dependent differences in

the rat. Pharmacology. 19f 209-214, 1979.

307. Zinkham WH, Childs B. Effect of vitamin K and

naphthalene metabolites on glutathione metabolism of

erythrocytes from normal newborns and patients with

naphthalene hemolytic anemia. Am J Pis Child. 94,

420, 1957.

'V,-.